C0042210||LbSapSal Vaccine
C1280551||Canine
C0446195||Leishmania chagasi
C0805586||Challenge
C0012984||Dogs
C0446195||L. chagasi
C0023272||L. infantum
C0042210||vaccine
C1280551||canine
C0023290||visceral leishmaniasis
C0023290||canine visceral leishmaniasis
C0003467||anxiety
C0086418||human
C0023290||visceral leishmaniasis
C0023290||visceral leishmaniasis
C0036158||sand fly
C0036100||salivary proteins
C0003320||immunogens
C1095819||Leishmania parasites
C1548483||anti-Leishmania vaccine
C4277607||immunogenicity
C0042210||"LbSapSal" vaccine
C0023271||L. braziliensis
C0003320||antigens
C0520481||saponin
C0001551||adjuvant
C0322761||Lutzomyia longipalpis
C0036098||salivary gland
C0012984||dogs
C0446195||L. chagasi
C0805586||challenge
C0020971||immunization
C0042210||LbSapSal
C0005516||biomarkers
C0041368||type I
C1456820||tumor necrosis factor [TNF]-α
C0123759||interleukin [IL]-12
C0021745||interferon [IFN]-γ
C0079189||cytokines
C0079189||type II cytokines
C0021758||IL-4
C0040690||TGF-β
C0805586||challenge
C0301872||immune response
C0042210||LbSapSal
C0020971||immunization
C0028128||nitric oxide
C0037993||spleen
C0042210||LbSapSal
C0042196||vaccination